Recent meta-analyses provide evidence supporting the use of baseline levels of CSF Aβ42 and tau as biomarkers for selecting individuals with mild cognitive impairment and AD pathology in clinical trials, significantly reducing sample size and trial costs [119, 121, 124]. The gene discussed is MAPT; the disease is Alzheimer disease.